Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Circadian Rhythm-Based NHT Timing in mHSPC
NCT06505278Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abiraterone, enzalutamide, apalutamide and rezvilutamide in prostate cancer (PCa) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Prostate Specific Antigen response rate at 3 months. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
abirateroneenzalutamideapalutamiderezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06505278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06505278.